|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, March 24, 2018 ) Sepsis Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Sepsis Disease Pipeline Drugs Assessment
Overview:
Sepsis is a potentiallylife-threatening or medical emergency condition in which the immune systems overrides its response to an infection. Sepsis develops when the chemicals are released into the bloodstream which causes the cascade of eventsthat lead to the inflammation throughout the body. In most of the cases, it may lead to the septic shock, which is medical emergency. According to Center for Disease Controll and Prevention (CDC), more than 1.5 millin people get Sepsis each year in U.S. and 250,000 people die each year
Sepsis can quickly progress to septic shock and may lead to death. A number of medications are used to treat the Sepsis including painkillers, vasoactive medications to improve blood pressure, insulin, corticosteroids and antibiotics via IV route.
A sample of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/sepsis-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By route of administration, sepsis pipeline drugs are segmented into
Oral
Parenteral
Others
By Trial Phase, Sepsis pipeline drugs are segmented as:
Preclinical Trials
Phase 1
Phase 2
Phase 3
By Company, Sepsis pipeline drugs are segmented as:
Bristol-Myers Squibb (U.S.)
Eisai Co., Ltd. (Japan)
Shionogi & Company, Limited (Japan)
Adrenomed AG (Germany)
Ferring Holding SA (Switzerland)
TiGenix (Belgium)
Others
To view TOC of this report is available upon request @https://www.precisionbusinessinsights.com/market-reports/sepsis-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
In December 2017, Adrenomed AG, announced today that the first patient with early septicshock has been dosed in the ADR-02 Phase-II study (AdrenOSS-2, NCT03085758)conducted in Germany, Belgium, France and the Netherlands.
In January 2017, TiGenix NV announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
Report Description:
Sepsis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Sepsis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Sepsis disease pipeline drugs development. This report studies the dynamics of the Sepsis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Sepsis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @https://www.precisionbusinessinsights.com/market-reports/sepsis-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
Provides the information related to universities and research institutes working in the therapeutics development
Report comprehensively covers the all active and discontinued studies
Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
Presents the prominent targets for drug development in each stage of clinical trial
Provides the in-depth analysis of each drug candidates in the clinical trial phases
Get access to full summary @https://www.precisionbusinessinsights.com/market-reports/sepsis-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @https://www.precisionbusinessinsights.com
Precision Business Insights
Satya Satya
866-598-1553
satya@pbigp.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
